Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SCAL getting to be a good volume day. Only started trading July 7th. do dd on their PR from 7/7.
Deewar25; gotta ETLC link on that Ledbed thing. Can't find, heard it was email blast? tia
Keep your peeps on SCAL.
ETLC, yes I bought in this a.m. Shakerzz & Ledbed recommending.
XKEM info from an article from another brd.
Thx to the poster from RB who posted this.
Nigeria Export Import Bank (NEXIM) has concluded plans to raise its share capital from N50 billion to N100 billion.
This is coming at a time when President Olusegun Obasanjo gave the management and board of the bank, a part on the back for a job well done.
The bank recently concluded a deal to fund a drug, NICOSAN, which would generate a yearly minimum of $5 million in foreign exchange in the first two years of operations from royalty payments and exports.
The drug, the first of its kind that manages sickle cell disorder was researched and patented by the National Institute for Pharmaceutical Research and Development (NIPRD). It will be manufactured in Nigeria with 100 per cent local raw materials, which President Obasanjo described as “a major landmark in our technological development as a nation”.
http://www.cometnewsonline.com/capital.html
XKEM info from an article from another brd.
Nigeria Export Import Bank (NEXIM) has concluded plans to raise its share capital from N50 billion to N100 billion.
This is coming at a time when President Olusegun Obasanjo gave the management and board of the bank, a part on the back for a job well done.
The bank recently concluded a deal to fund a drug, NICOSAN, which would generate a yearly minimum of $5 million in foreign exchange in the first two years of operations from royalty payments and exports.
The drug, the first of its kind that manages sickle cell disorder was researched and patented by the National Institute for Pharmaceutical Research and Development (NIPRD). It will be manufactured in Nigeria with 100 per cent local raw materials, which President Obasanjo described as “a major landmark in our technological development as a nation”.
http://www.cometnewsonline.com/capital.html
SCAL,no doubt she is getting "JIGGY" dd last PR!
http://bigcharts.marketwatch.com/news/articles.asp?guid={25B571B2-7BAE-4FD4-AFED-B031EE960117}&n...
Go CMKM Diamond (private co.) lol!em
SCAL. dd their last pr. eom
SCAL sleeper ready to be awaken. A little more volume and this explodes. They are the leader, see below... do dd. It's a sleeper...
Stem Cell Authority Ltd.(TM) Open for Public Trading
FRIDAY, JULY 07, 2006 10:34 AM
- PR Newswire
SCAL
AKRON, Ohio, July 7, 2006 /PRNewswire-FirstCall via COMTEX/ -- NASDAQ authorized Stem Cell Authority Ltd. (SCAL) , the company which possesses the exclusive rights for the collection and storage of human umbilical cord matrix stem cells, to be publicly traded on July 6, 2006.
The Kansas State University Research Foundation has filed an application for a patent pertaining to the methods for the collection, storage and biotechnology and therapeutic use of umbilical cord matrix stem cells, and has granted Stem Cell Authority Ltd. and its subsidiary company the exclusive license to collect and cryogenically store human umbilical cord matrix stem cells. Thus, the collection and storage of human pluripotent umbilical cord matrix stem cell must be authorized by Stem Cell Authority Ltd. The company also has the right to grant sublicenses.
Recent evidence indicates that the umbilical cord matrix stem cells can differentiate into neurons, glia, skeletal muscle cells, heart muscle cells, bone cells, cartilage cells and liver cells. Published work indicates that the human umbilical cord matrix stem cells are therapeutically useful in an animal model of Parkinson's disease. Therefore, the umbilical cord matrix stem cells may have the potential for treating neurological diseases. In contrast, umbilical cord blood stem cells are used clinically to treat conditions calling for bone marrow stem cell transplant. These diseases include certain cancers and in-borne errors in metabolism.
Stem Cell Authority Ltd. collects the matrix cells from the Wharton's jelly which is within the human umbilical cord. The matrix cells are collected safely and painlessly without risk to the child after birth. The collection of the matrix stem cell is compatible with collection of umbilical cord blood stem cells. Thus, Stem Cell Authority Ltd. is the ethical and non- controversial alternative to obtain human stem cells for cryogenic storage of both umbilical cord blood and the matrix stem cells. Stem Cell Authority Ltd. has the exclusive right to offer this service to its customers, placing it in a strong position within the biotech market.
Stem Cell Authority Ltd. is the only entity worldwide that is permitted to collect and store the umbilical cord's pluripotent or matrix stem cells, which have the potential to be one of the most important sources of stem cells available. The company is poised to become a market leader in this expanding biotech industry.
SOURCE Stem Cell Authority Ltd.
C. Bernard Cardwell, CEO of Stem Cell Authority Ltd., +1-330 835-0200
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
HEY CMKX ROCKS! Now pay up!
Shakerzz, your sick! Hey have a good time at the party! That pic is pretty bad! CWAZY GUY!
Shakerzzz, wud u do? Buy a bunch of XKEM or what??? Nice close for starters and a little lite at that tunnel.
Covering Up Naked Shorts by an ex SEC chairman
Thx Elvis-is-here.
Harvey Pitt 07.11.06, 3:00 PM ET
Harvey Pitt
Click here for more on Harvey Pitt
Today's Top Stories
• Oil Hits $76 On Mideast Violence
• Stocks Slide Under Oil Pressure
• Eurotunnel Seeks Creditor Protection
• Ghosn: GM Deal Would Need Equity Stake
• Pepsi Beats Profit Expectations
Most Popular Stories
America's Youngest CEOs
150 Cheap Places To Live
Most Expensive Hotels In The US
Young Billionaires
Most Popular Cars For Men And Women
Washington, D.C. - As crisis after crisis afflicts the business community and our capital markets, all too often the response is a form of reverse laissez faire. Business waits for government to tell it three things: if it has done something wrong, why it's wrong and how to fix it. The ineluctable result is that, like Rick's crooked police pal, Captain Renault, in the movie Casablanca, we're "shocked, shocked to discover" we don't like the government's responses.
Unfortunately (or fortunately, depending upon one's perspective), the business community's repeated crises has given it an opportunity to modify its laissez faire attitude. But so far, it hasn't shown the resolve.
A case in point is the current crisis in short-selling. Short-selling is a useful and critically important capital market phenomenon, but only if done appropriately. Among other things, it provides essential liquidity in thinly traded stocks, enables thoughtful traders to limit the degree of risk to which their portfolio holdings are subject and serves as an effective counterbalance to the herd mentality too many analysts and investors exhibit.
In a real sense, short-sellers are marketplace lone wolves (or, more precisely, lone bears), ignoring the herd, trading against conventional wisdom and sometimes uncovering real corporate frauds far ahead of self-regulators, regulators, prosecutors or even plaintiffs' attorneys. On the other hand, companies have been victimized by professional short-sellers, some of whom, on occasion, resort to dubious tactics--and even market manipulation--to ensure the success of their bearish gambles.
The problem with our current short-selling paradigm isn't short-selling itself, as many CEOs might prefer to believe. It's the ability of short-sellers to sell stocks they haven't actually borrowed in advance of their short sale. It's a phenomenon described, somewhat lasciviously, as "naked" short-selling. Naked shorts expose sellers and those "linked" to the sales to the risk that, when settlement day arrives and shares must be delivered, the short-seller won't have the necessary shares available.
The U.S. Securities and Exchange Commission recognizes this is a problem, but its efforts thus far haven't generated much success. In 2004, the agency adopted Regulation SHO, which, among other things, requires short-sellers and their brokers to have reasonable grounds to believe securities being sold short can be "borrowed so that [they] can be delivered at settlement."
What constitutes "reasonable grounds?" That depends on whom you ask. Many prime brokers, for example, satisfy the requirement of reasonable grounds by assuming that, if large long positions reside somewhere in-house, they can borrow from those long positions without bothering to check if the shares are actually available for borrowing and without ascertaining if those same shares have already provided reasonable grounds to permit another short sale of the same security.
This can lead to "over-shorting" of securities, a phenomenon in which the number of shares shorted can even exceed the number of shares physically available for trading. To combat naked shorting of heavily shorted securities, technically known as "threshold" securities, the SEC's rule requires brokers planning to effect a short sale in a threshold security to have in place, prior to shorting, a definitive arrangement to borrow those shares.
In addition, in May 2006, self-regulatory organizations adopted SEC guidance that any shares bought-in by a broker to satisfy undelivered shorted shares must be applied to the earliest undelivered shorts. This essentially requires brokers to buy-in all shares they've failed to deliver once any shares must be bought-in. In January 2005, there were 520 threshold securities. Today, even with the SEC's efforts, there are still 235, including some that were on the list of threshold securities back when the concept was first created. On Wednesday, July 12, the SEC takes its third stab at trying to solve the problem.
Because of the legitimate concerns this situation engenders, state governments are roiling the waters. Utah has adopted its own law to dictate how short transactions should be effected, and Connecticut has threatened to enter the fray as well. We're in danger of facing a quilted patchwork of state regulations to govern an important facet of what are uniquely national (and global) markets.
At the same time, plaintiffs' lawyers are pressing lawsuits accusing brokers of collecting fees for lending shares to short-sellers without actually having borrowed the shares. If these allegations are proved, the result could be a black eye for the brokerage community, large payments to aggrieved parties and much tighter regulation.
The securities industry and clearing agencies don't seem to recognize that it's only a matter of time before these problems catch up with them and kill off the goose that is, at present, laying very golden eggs. The securities industry needs to seize control and propose effective remedies to increase transparency in stock lending and borrowing.
Securities and clearing firms need to act quickly. Or else they, to paraphrase Will Rogers, will have to be content to live with even more government than they're already paying for.
Harvey L. Pitt is the CEO of Kalorama Partners. He was chairman of the SEC from 2001 to 2003, currently serves on the audit committees of Approva and the National Cathedral School, and writes a monthly column for ComplianceWeek.
Covering Up Naked Shorts by an ex SEC chairman
Thx Elvis-is-here.
Harvey Pitt 07.11.06, 3:00 PM ET
Harvey Pitt
Click here for more on Harvey Pitt
Today's Top Stories
• Oil Hits $76 On Mideast Violence
• Stocks Slide Under Oil Pressure
• Eurotunnel Seeks Creditor Protection
• Ghosn: GM Deal Would Need Equity Stake
• Pepsi Beats Profit Expectations
Most Popular Stories
America's Youngest CEOs
150 Cheap Places To Live
Most Expensive Hotels In The US
Young Billionaires
Most Popular Cars For Men And Women
Washington, D.C. - As crisis after crisis afflicts the business community and our capital markets, all too often the response is a form of reverse laissez faire. Business waits for government to tell it three things: if it has done something wrong, why it's wrong and how to fix it. The ineluctable result is that, like Rick's crooked police pal, Captain Renault, in the movie Casablanca, we're "shocked, shocked to discover" we don't like the government's responses.
Unfortunately (or fortunately, depending upon one's perspective), the business community's repeated crises has given it an opportunity to modify its laissez faire attitude. But so far, it hasn't shown the resolve.
A case in point is the current crisis in short-selling. Short-selling is a useful and critically important capital market phenomenon, but only if done appropriately. Among other things, it provides essential liquidity in thinly traded stocks, enables thoughtful traders to limit the degree of risk to which their portfolio holdings are subject and serves as an effective counterbalance to the herd mentality too many analysts and investors exhibit.
In a real sense, short-sellers are marketplace lone wolves (or, more precisely, lone bears), ignoring the herd, trading against conventional wisdom and sometimes uncovering real corporate frauds far ahead of self-regulators, regulators, prosecutors or even plaintiffs' attorneys. On the other hand, companies have been victimized by professional short-sellers, some of whom, on occasion, resort to dubious tactics--and even market manipulation--to ensure the success of their bearish gambles.
The problem with our current short-selling paradigm isn't short-selling itself, as many CEOs might prefer to believe. It's the ability of short-sellers to sell stocks they haven't actually borrowed in advance of their short sale. It's a phenomenon described, somewhat lasciviously, as "naked" short-selling. Naked shorts expose sellers and those "linked" to the sales to the risk that, when settlement day arrives and shares must be delivered, the short-seller won't have the necessary shares available.
The U.S. Securities and Exchange Commission recognizes this is a problem, but its efforts thus far haven't generated much success. In 2004, the agency adopted Regulation SHO, which, among other things, requires short-sellers and their brokers to have reasonable grounds to believe securities being sold short can be "borrowed so that [they] can be delivered at settlement."
What constitutes "reasonable grounds?" That depends on whom you ask. Many prime brokers, for example, satisfy the requirement of reasonable grounds by assuming that, if large long positions reside somewhere in-house, they can borrow from those long positions without bothering to check if the shares are actually available for borrowing and without ascertaining if those same shares have already provided reasonable grounds to permit another short sale of the same security.
This can lead to "over-shorting" of securities, a phenomenon in which the number of shares shorted can even exceed the number of shares physically available for trading. To combat naked shorting of heavily shorted securities, technically known as "threshold" securities, the SEC's rule requires brokers planning to effect a short sale in a threshold security to have in place, prior to shorting, a definitive arrangement to borrow those shares.
In addition, in May 2006, self-regulatory organizations adopted SEC guidance that any shares bought-in by a broker to satisfy undelivered shorted shares must be applied to the earliest undelivered shorts. This essentially requires brokers to buy-in all shares they've failed to deliver once any shares must be bought-in. In January 2005, there were 520 threshold securities. Today, even with the SEC's efforts, there are still 235, including some that were on the list of threshold securities back when the concept was first created. On Wednesday, July 12, the SEC takes its third stab at trying to solve the problem.
Because of the legitimate concerns this situation engenders, state governments are roiling the waters. Utah has adopted its own law to dictate how short transactions should be effected, and Connecticut has threatened to enter the fray as well. We're in danger of facing a quilted patchwork of state regulations to govern an important facet of what are uniquely national (and global) markets.
At the same time, plaintiffs' lawyers are pressing lawsuits accusing brokers of collecting fees for lending shares to short-sellers without actually having borrowed the shares. If these allegations are proved, the result could be a black eye for the brokerage community, large payments to aggrieved parties and much tighter regulation.
The securities industry and clearing agencies don't seem to recognize that it's only a matter of time before these problems catch up with them and kill off the goose that is, at present, laying very golden eggs. The securities industry needs to seize control and propose effective remedies to increase transparency in stock lending and borrowing.
Securities and clearing firms need to act quickly. Or else they, to paraphrase Will Rogers, will have to be content to live with even more government than they're already paying for.
Harvey L. Pitt is the CEO of Kalorama Partners. He was chairman of the SEC from 2001 to 2003, currently serves on the audit committees of Approva and the National Cathedral School, and writes a monthly column for ComplianceWeek.
Shakerz, over 3K in members? Good one, now lets make mountains out of mole hills in the USA, Good start on XKEM today. What is your email. I have a good one. or e-me at narveson1@hotmail.com
SCAL do some dd on them. Called them yesterday and they said their website will be up soon. Would not give a date as they are a public co. They have exclusive rights for stem cells farming from babies umbilicle cords. Get in before they are well known. Crazy Cramer pumpin biotech.
They just started trading Friday July 6th.
link for pr:
http://bigcharts.marketwatch.com/news/articles.asp?guid={25B571B2-7BAE-4FD4-AFED-B031EE960117}&n...
website under construction:
http://www.stemcellauthority.com/
They just started trading Friday July 6th.
SCAL do some dd on them. Called them yesterday and they said their website will be up soon. Would not give a date as they are a public co. They have exclusive rights for stem cells farming from babies umbilicle cords. Get in before they are well known. Crazy Cramer pumpin biotech.
They just started trading Friday July 6th.
link for pr:
http://bigcharts.marketwatch.com/news/articles.asp?guid={25B571B2-7BAE-4FD4-AFED-B031EE960117}&n...
website under construction:
http://www.stemcellauthority.com/
They just started trading Friday July 6th.
DowntheHole & XKEM, I hope the mm's were shaking for the possible Green Baron pick tomorrow. Momo-a gogo....
Tuesday, July 11, 2006
July 2006 Focus Stock Pick to be Released Tomorrow, Wed. July 12 at 1:30 pm EST
It has been worth the wait … Triple digit returns expected for new Green Baron pick! Please set your alerts!
The Green Baron Report has demonstrated extreme patience over the past several months. We have been eager to present our members with a stock that we have no doubt would be a huge winner, but time and time again we have found reason to stay away. We also predicted that the stock market was due for a sell off that was visibly seen in May and June.
Now that we have seen some stabilization in stock prices over the past several weeks, we are more comfortable releasing a new pick. In particular, there is one stock we have had our eye on for months that has retreated back to extremely oversold prices. At the time we are writing these words, the stock is pegged at the year low. Our hope in rushing you our new pick profile tomorrow is that our members will get a chance to buy the stock at the perfect time in front of a multi-triple digit move.
The potential of our new pick is simply staggering. As usual, the new pick will be released to members via an email during market trading hours at about 1:30 pm EST tomorrow, Wednesday July 12. The stock will officially be our 53rd fully profiled stock for our storied home page and we truly believe it could wind up being our biggest percentage gainer ever. There are developments in motion that could make this stock a ten bagger in a very short period of time. This stock has already traded at levels that are over 300% above the current price this year.
We don’t want to give too many hints at this time, but we will tell you all that the stock trades in a tight range below .05 per share. We consider the stock an absolute steal right now, and can make a strong case to own this stock at twice the price based on current earnings alone. The growth plans are what makes this stock a potential home run. This is the stock The Green Baron Report has been waiting for all year!
KTCC somebody just bought 40k worth. Gap up please in the a.m. adios
DowntheHole, did just that.XKEM manana!
KTCC good corp. gltya
SCAL, improtant information from the pr last Friday...
Stem Cell Authority Ltd. is the only entity worldwide that is permitted to collect and store the umbilical cord's pluripotent or matrix stem cells, which have the potential to be one of the most important sources of stem cells available. The company is poised to become a market leader in this expanding biotech industry.
SCAL, improtant information from the pr last Friday...
Stem Cell Authority Ltd. is the only entity worldwide that is permitted to collect and store the umbilical cord's pluripotent or matrix stem cells, which have the potential to be one of the most important sources of stem cells available. The company is poised to become a market leader in this expanding biotech industry.
SCAL website. I beleive this is a great op. to get in before others.
http://www.stemcellauthority.com/
SCAL website. I beleive this is a great op. to get in before others.
http://www.stemcellauthority.com/
SCAL stock symbol. I feel this is a good pick, please read the pr from Friday. It is powerful. Any comments and I don't care for Cramer, but sometimes he can pull a following into biotech. Get in before the rest into Biotech, imo. DO DD!
By: narvo0
07 Jul 2006, 04:28 PM EDT
Msg. 326327 of 326472
Jump to msg. #
SCAL:This maybe the best news I've seen in awhile. Cramer says to get in Biotech and you know his following. I am in this as of late today.
This may be a very good secret right now.
do dd.
Stem Cell Authority Ltd.(TM) Open for Public Trading
FRIDAY, JULY 07, 2006 10:34 AM
- PR Newswire
SCAL
AKRON, Ohio, July 7, 2006 /PRNewswire-FirstCall via COMTEX/ -- NASDAQ authorized Stem Cell Authority Ltd. (SCAL) , the company which possesses the exclusive rights for the collection and storage of human umbilical cord matrix stem cells, to be publicly traded on July 6, 2006.
The Kansas State University Research Foundation has filed an application for a patent pertaining to the methods for the collection, storage and biotechnology and therapeutic use of umbilical cord matrix stem cells, and has granted Stem Cell Authority Ltd. and its subsidiary company the exclusive license to collect and cryogenically store human umbilical cord matrix stem cells. Thus, the collection and storage of human pluripotent umbilical cord matrix stem cell must be authorized by Stem Cell Authority Ltd. The company also has the right to grant sublicenses.
Recent evidence indicates that the umbilical cord matrix stem cells can differentiate into neurons, glia, skeletal muscle cells, heart muscle cells, bone cells, cartilage cells and liver cells. Published work indicates that the human umbilical cord matrix stem cells are therapeutically useful in an animal model of Parkinson's disease. Therefore, the umbilical cord matrix stem cells may have the potential for treating neurological diseases. In contrast, umbilical cord blood stem cells are used clinically to treat conditions calling for bone marrow stem cell transplant. These diseases include certain cancers and in-borne errors in metabolism.
Stem Cell Authority Ltd. collects the matrix cells from the Wharton's jelly which is within the human umbilical cord. The matrix cells are collected safely and painlessly without risk to the child after birth. The collection of the matrix stem cell is compatible with collection of umbilical cord blood stem cells. Thus, Stem Cell Authority Ltd. is the ethical and non- controversial alternative to obtain human stem cells for cryogenic storage of both umbilical cord blood and the matrix stem cells. Stem Cell Authority Ltd. has the exclusive right to offer this service to its customers, placing it in a strong position within the biotech market.
Stem Cell Authority Ltd. is the only entity worldwide that is permitted to collect and store the umbilical cord's pluripotent or matrix stem cells, which have the potential to be one of the most important sources of stem cells available. The company is poised to become a market leader in this expanding biotech industry.
SOURCE Stem Cell Authority Ltd.
C. Bernard Cardwell, CEO of Stem Cell Authority Ltd., +1-330 835-0200
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
http://bigcharts.marketwatch.com/news/articles.asp?guid={25B571B2-7BAE-4FD4-AFED-B031EE960117}&n...
Thx to the poster that brought this here Friday! Got in cheap!
SCAL stock symbol. I feel this is a good pick, please read the pr from Friday. It is powerful. Any comments and I don't care for Cramer, but sometimes he can pull a following into biotech. Get in before the rest into Biotech, imo. DO DD!
By: narvo0
07 Jul 2006, 04:28 PM EDT
Msg. 326327 of 326472
Jump to msg. #
SCAL:This maybe the best news I've seen in awhile. Cramer says to get in Biotech and you know his following. I am in this as of late today.
This may be a very good secret right now.
do dd.
Stem Cell Authority Ltd.(TM) Open for Public Trading
FRIDAY, JULY 07, 2006 10:34 AM
- PR Newswire
SCAL
AKRON, Ohio, July 7, 2006 /PRNewswire-FirstCall via COMTEX/ -- NASDAQ authorized Stem Cell Authority Ltd. (SCAL) , the company which possesses the exclusive rights for the collection and storage of human umbilical cord matrix stem cells, to be publicly traded on July 6, 2006.
The Kansas State University Research Foundation has filed an application for a patent pertaining to the methods for the collection, storage and biotechnology and therapeutic use of umbilical cord matrix stem cells, and has granted Stem Cell Authority Ltd. and its subsidiary company the exclusive license to collect and cryogenically store human umbilical cord matrix stem cells. Thus, the collection and storage of human pluripotent umbilical cord matrix stem cell must be authorized by Stem Cell Authority Ltd. The company also has the right to grant sublicenses.
Recent evidence indicates that the umbilical cord matrix stem cells can differentiate into neurons, glia, skeletal muscle cells, heart muscle cells, bone cells, cartilage cells and liver cells. Published work indicates that the human umbilical cord matrix stem cells are therapeutically useful in an animal model of Parkinson's disease. Therefore, the umbilical cord matrix stem cells may have the potential for treating neurological diseases. In contrast, umbilical cord blood stem cells are used clinically to treat conditions calling for bone marrow stem cell transplant. These diseases include certain cancers and in-borne errors in metabolism.
Stem Cell Authority Ltd. collects the matrix cells from the Wharton's jelly which is within the human umbilical cord. The matrix cells are collected safely and painlessly without risk to the child after birth. The collection of the matrix stem cell is compatible with collection of umbilical cord blood stem cells. Thus, Stem Cell Authority Ltd. is the ethical and non- controversial alternative to obtain human stem cells for cryogenic storage of both umbilical cord blood and the matrix stem cells. Stem Cell Authority Ltd. has the exclusive right to offer this service to its customers, placing it in a strong position within the biotech market.
Stem Cell Authority Ltd. is the only entity worldwide that is permitted to collect and store the umbilical cord's pluripotent or matrix stem cells, which have the potential to be one of the most important sources of stem cells available. The company is poised to become a market leader in this expanding biotech industry.
SOURCE Stem Cell Authority Ltd.
C. Bernard Cardwell, CEO of Stem Cell Authority Ltd., +1-330 835-0200
http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
http://bigcharts.marketwatch.com/news/articles.asp?guid={25B571B2-7BAE-4FD4-AFED-B031EE960117}&n...
Thx to the poster that brought this here Friday! Got in cheap!
SHAKERZZZ
Shakerzzz.
what's your email address. I have somesing.
Or e-me at
narveson1@hotmail.com
Shalerzzz.
what's your email address. I have somesing.
XKEM article July 6th 2006
LATEST:
Last Updated: July 6th, 2006
July 6th, 2006
Obasanjo to commission sickle cell drug factory today
E-MAIL THIS PRINT THIS Most Viewed
http://www.businessdayonline.com/?c=44&a=7409
A local factory that would immediately commence the production of NICOSAN- an anti-sickling drug, will be commissioned today by President Olusegun Obsanjo.
Ayodele Coker, Director General of SHESTCO who disclosed this in Abuja yesterday explained that NICONSAN is a drug first developed by the National Institute for Pharmaceutical Research and Development (NIPRD) for the management of sickle cell disease.
He said that NICOSAN consists of a mixture of extracts from four tropical plants, some of which are cultivated and found in the wild both within and outside Nigeria Coker stressed that all necessary precautions had been taken to ensure safety of the products as well as continuity in the production.
According to him, the Gamma irradiation facility is to be used for food preservation, sterilisation of pharmaceutical and medical devices, as well as polymerisation and other industrial applications.
Cker said that "the drug, to be used in the treatment of sickle cell diseases, is being produced by a pharmaceutical company-Xechem-Nigeria and has been tested locally and international at Philadelphia Children’s Hospital in the United States."
The drug which Coker said has been approved by the National Agency for Food and Drug Administration and Control (NAFDAC) is also been recognised by the World Health Organisation (WHO) for the treatment of sickle cell diseases .
Coker explained that the Gamma Irradation facility is for food security and preservation of agricultural products which will cut down the loss from waste of harvested crops experienced annually stressing "more than 55% of our harvested crops are wasted thus the need for the facility and we want to cut down on this loss".
"WE are confident this will help in the reduction of prices of foodstuffs all year round. With the Gamma Irradiation Facility, you can delay the ripening period period, retain freshness and admittance of exported agriculture products in the markets. Products that go through the facility will be 100% safe for human consumption as there is no room for error.
More In Headlines
» IGI introduces new products at...
» Southern senators screen...
» Unilever confident of better...
» Niger Delta pivotal to success...
» Enron founder Lay dies at 64
» Skye Bank offers more ATM...
» MTN shareholders approve...
XKEM article July 6th 2006
LATEST:
Last Updated: July 6th, 2006
July 6th, 2006
Obasanjo to commission sickle cell drug factory today
E-MAIL THIS PRINT THIS Most Viewed
http://www.businessdayonline.com/?c=44&a=7409
A local factory that would immediately commence the production of NICOSAN- an anti-sickling drug, will be commissioned today by President Olusegun Obsanjo.
Ayodele Coker, Director General of SHESTCO who disclosed this in Abuja yesterday explained that NICONSAN is a drug first developed by the National Institute for Pharmaceutical Research and Development (NIPRD) for the management of sickle cell disease.
He said that NICOSAN consists of a mixture of extracts from four tropical plants, some of which are cultivated and found in the wild both within and outside Nigeria Coker stressed that all necessary precautions had been taken to ensure safety of the products as well as continuity in the production.
According to him, the Gamma irradiation facility is to be used for food preservation, sterilisation of pharmaceutical and medical devices, as well as polymerisation and other industrial applications.
Cker said that "the drug, to be used in the treatment of sickle cell diseases, is being produced by a pharmaceutical company-Xechem-Nigeria and has been tested locally and international at Philadelphia Children’s Hospital in the United States."
The drug which Coker said has been approved by the National Agency for Food and Drug Administration and Control (NAFDAC) is also been recognised by the World Health Organisation (WHO) for the treatment of sickle cell diseases .
Coker explained that the Gamma Irradation facility is for food security and preservation of agricultural products which will cut down the loss from waste of harvested crops experienced annually stressing "more than 55% of our harvested crops are wasted thus the need for the facility and we want to cut down on this loss".
"WE are confident this will help in the reduction of prices of foodstuffs all year round. With the Gamma Irradiation Facility, you can delay the ripening period period, retain freshness and admittance of exported agriculture products in the markets. Products that go through the facility will be 100% safe for human consumption as there is no room for error.
More In Headlines
» IGI introduces new products at...
» Southern senators screen...
» Unilever confident of better...
» Niger Delta pivotal to success...
» Enron founder Lay dies at 64
» Skye Bank offers more ATM...
» MTN shareholders approve...
http://www.businessdayonline.com/?c=44&a=7409
XKEM article July 6th 2006
LATEST:
Last Updated: July 6th, 2006
July 6th, 2006
Obasanjo to commission sickle cell drug factory today
E-MAIL THIS PRINT THIS Most Viewed
http://www.businessdayonline.com/?c=44&a=7409
A local factory that would immediately commence the production of NICOSAN- an anti-sickling drug, will be commissioned today by President Olusegun Obsanjo.
Ayodele Coker, Director General of SHESTCO who disclosed this in Abuja yesterday explained that NICONSAN is a drug first developed by the National Institute for Pharmaceutical Research and Development (NIPRD) for the management of sickle cell disease.
He said that NICOSAN consists of a mixture of extracts from four tropical plants, some of which are cultivated and found in the wild both within and outside Nigeria Coker stressed that all necessary precautions had been taken to ensure safety of the products as well as continuity in the production.
According to him, the Gamma irradiation facility is to be used for food preservation, sterilisation of pharmaceutical and medical devices, as well as polymerisation and other industrial applications.
Cker said that "the drug, to be used in the treatment of sickle cell diseases, is being produced by a pharmaceutical company-Xechem-Nigeria and has been tested locally and international at Philadelphia Children’s Hospital in the United States."
The drug which Coker said has been approved by the National Agency for Food and Drug Administration and Control (NAFDAC) is also been recognised by the World Health Organisation (WHO) for the treatment of sickle cell diseases .
Coker explained that the Gamma Irradation facility is for food security and preservation of agricultural products which will cut down the loss from waste of harvested crops experienced annually stressing "more than 55% of our harvested crops are wasted thus the need for the facility and we want to cut down on this loss".
"WE are confident this will help in the reduction of prices of foodstuffs all year round. With the Gamma Irradiation Facility, you can delay the ripening period period, retain freshness and admittance of exported agriculture products in the markets. Products that go through the facility will be 100% safe for human consumption as there is no room for error.
More In Headlines
» IGI introduces new products at...
» Southern senators screen...
» Unilever confident of better...
» Niger Delta pivotal to success...
» Enron founder Lay dies at 64
» Skye Bank offers more ATM...
» MTN shareholders approve...
XKEM article July 6th 2006
LATEST:
Last Updated: July 6th, 2006
July 6th, 2006
Obasanjo to commission sickle cell drug factory today
E-MAIL THIS PRINT THIS Most Viewed
http://www.businessdayonline.com/?c=44&a=7409
A local factory that would immediately commence the production of NICOSAN- an anti-sickling drug, will be commissioned today by President Olusegun Obsanjo.
Ayodele Coker, Director General of SHESTCO who disclosed this in Abuja yesterday explained that NICONSAN is a drug first developed by the National Institute for Pharmaceutical Research and Development (NIPRD) for the management of sickle cell disease.
He said that NICOSAN consists of a mixture of extracts from four tropical plants, some of which are cultivated and found in the wild both within and outside Nigeria Coker stressed that all necessary precautions had been taken to ensure safety of the products as well as continuity in the production.
According to him, the Gamma irradiation facility is to be used for food preservation, sterilisation of pharmaceutical and medical devices, as well as polymerisation and other industrial applications.
Cker said that "the drug, to be used in the treatment of sickle cell diseases, is being produced by a pharmaceutical company-Xechem-Nigeria and has been tested locally and international at Philadelphia Children’s Hospital in the United States."
The drug which Coker said has been approved by the National Agency for Food and Drug Administration and Control (NAFDAC) is also been recognised by the World Health Organisation (WHO) for the treatment of sickle cell diseases .
Coker explained that the Gamma Irradation facility is for food security and preservation of agricultural products which will cut down the loss from waste of harvested crops experienced annually stressing "more than 55% of our harvested crops are wasted thus the need for the facility and we want to cut down on this loss".
"WE are confident this will help in the reduction of prices of foodstuffs all year round. With the Gamma Irradiation Facility, you can delay the ripening period period, retain freshness and admittance of exported agriculture products in the markets. Products that go through the facility will be 100% safe for human consumption as there is no room for error.
More In Headlines
» IGI introduces new products at...
» Southern senators screen...
» Unilever confident of better...
» Niger Delta pivotal to success...
» Enron founder Lay dies at 64
» Skye Bank offers more ATM...
» MTN shareholders approve...
http://www.businessdayonline.com/?c=44&a=7409
XKEM post,By: dragon52
06 Jul 2006, 02:11 PM EDT
Msg. 809496 of 809508
Jump to msg. #
XKEM insight... nice very nice
By: alexng00
06 Jul 2006, 02:09 PM EDT
Msg. 71693 of 71699
Jump to msg. #
Just get a status from my contact who was at the launch :
"The president of Nigeria, Minister of Scieces and technology, Minister of Health, Minister of Information, Nafdac representants, Business people, Nigeria TV, newspapers and other guests are at the launch, there are around 400-500 people at the launch. The factory is big and the drug will be produced immediately following the launch and sold on the Nigeria market first. The President commissionned the factory, all the news tomorrow on newspaper and TV."
It's a huge and important event as we all know, glta.
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
Char, I hear ya there. trying to get meself.
Give me rice, give me beans, give me corn...I give u nicosan..make u well keemosawbee.
BlueHorse, speaking of Bristol and XKEM, lol! Look at this..just found it.
By: hinchsagain
06 Jul 2006, 01:57 PM EDT
Msg. 809486 of 809500
Jump to msg. #
XKEM wowww more ALERTS! Posted by: africaguru
In reply to: None Date:7/6/2006 1:55:46 PM
Post #of 18825
10 minutes ago .... look this alert!!!!
Fecha: Thu, 6 Jul 2006 19:39:22 +0200 (CEST)
Asunto: [SuperPicks] XKEm.ob Last Minute BRISTOL MYERS Interest in Hemoxin , TAXOL and Research of NEW natural DRUGS.
XKEm.ob Last Minute BRISTOL MYERS Interest in Hemoxin , TAXOL and Research of NEW natural DRUGS.
Xechem International headquarters announce conversations with BMY.
http://www.investorshub.com/boards/read_msg.asp?message_id=11904224
BlurHorseShoe, LOL! That's freakin TRUE! LOL! Azzholes
scaring everyone to death. Make some moola. Love these types of rumours! How bout throw in Bristol Myer Squibb in the loop!
XKEM, buyout rumour...love it!em
Okay who all bought back into XKEM???
XKEM for the ones still in it,
do dd.
By: NIZAK
05 Jul 2006, 05:24 PM EDT
Msg. 69953 of 69988
Jump to msg. #
Anybody experienced in trading pennies knows that this happens.Buy on rumor/speculation, sell on news.The positive side to this stock is that there is much more in the pipeline to rebound this above levels we saw today. Face it, how many days are you going to look at your account balance seeing it's up as much as 1000% and not act on it.Taking profits is a part of this game, and should be. After all, how many are here just to own a co. that will help people with a disease, and not profit from it, No One! This will attract alot of media coverage over the next couple of days,if you care to sell thats your choice, it all comes down to how much you want to profit from this. Some are content with 100%, some 1000, some 2000. whatever works best for you is the route to take. I fully anticipate this stock will be trading back in the .09 range by this time tomorrow. JMO.
XKEM for the ones still in it,
do dd.
By: NIZAK
05 Jul 2006, 05:24 PM EDT
Msg. 69953 of 69988
Jump to msg. #
Anybody experienced in trading pennies knows that this happens.Buy on rumor/speculation, sell on news.The positive side to this stock is that there is much more in the pipeline to rebound this above levels we saw today. Face it, how many days are you going to look at your account balance seeing it's up as much as 1000% and not act on it.Taking profits is a part of this game, and should be. After all, how many are here just to own a co. that will help people with a disease, and not profit from it, No One! This will attract alot of media coverage over the next couple of days,if you care to sell thats your choice, it all comes down to how much you want to profit from this. Some are content with 100%, some 1000, some 2000. whatever works best for you is the route to take. I fully anticipate this stock will be trading back in the .09 range by this time tomorrow. JMO.